BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

J Hepatol

BCLC Group, Liver Unit, ICMDM, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain. Electronic address:

Published: March 2022

There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866082PMC
http://dx.doi.org/10.1016/j.jhep.2021.11.018DOI Listing

Publication Analysis

Top Keywords

bclc strategy
4
strategy prognosis
4
prognosis prediction
4
prediction treatment
4
treatment recommendation
4
recommendation 2022
4
2022 update
4
update major
4
major advances
4
advances armamentarium
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!